Ionis Pharmaceuticals

Ionis Pharmaceuticals

Yahoo Finance • 9 days ago

NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss

Swiss pharma giant Novartis AG NVS reported third-quarter 2026 core earnings per share (excluding one-time charges) of $2.46, which beat the Zacks Consensus Estimate of $2.25. The figure increased 9% from $2.25 reported a year ago. The bo... Full story

Yahoo Finance • 13 days ago

Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

– Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to placebo at 37 weeks with consistent treatment effects across all prespecified patient subgroups – – Sefaxersen... Full story

Yahoo Finance • 16 days ago

Severe Hypertriglyceridemia Market Set for Growth During the Forecast Period (2026-2036) Following Approval of Ionis' TRYNGOLZA and Emergence of Novel Therapies | DelveInsight

The severe hypertriglyceridemia market is expected to experience steady growth, driven by the rising prevalence of obesity, diabetes, metabolic syndrome, and other cardiometabolic disorders associated with elevated triglyceride levels. Add... Full story

Yahoo Finance • 20 days ago

Lilly, Pfizer, J&J among winners of EU drug recommendations this month

[EU European Union Flags Side by Side Berlaymont Building Brussels Belgium] Mlenny/iStock via Getty Images An expert panel of the EU drug regulator endorsed six new medicines and five label expansions [https://www.ema.europa.eu/en/news/me... Full story

Yahoo Finance • last month

Cathie Wood Makes $64 Million Bet on Two Stocks

This article first appeared on GuruFocus. Cathie Wood's Ark Invest made a fresh round of high-conviction bets last week, adding heavily to Meta Platforms (NASDAQ:META) and Rocket Lab (NASDAQ:RKLB) while cutting exposure to several technol... Full story

Yahoo Finance • last month

Cathie Wood's Ark Invest weekly recap: boosts Meta, Rocket Lab; cuts Tempus AI, CrowdStrike

Cathie Wood’s Ark Invest boosted its technology, biotechnology, and space exposure last week, led by purchases of more than 51K shares of Meta Platforms (META [https://seekingalpha.com/symbol/META]) worth $38.2M and roughly 360K shares of... Full story

Yahoo Finance • last month

Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?

On September 1, 2026, the Wall Street Journal first reported that Novartis AG (NYSE:NVS) paused eight clinical trials of its experimental CAR-T cell therapy rap-cel in autoimmune and neurological conditions, including lupus, rheumatoid art... Full story

Yahoo Finance • last month

Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs

Ionis Pharmaceuticals IONS announced positive results from two partnered programs, both of which are in phase III development. IONS Secures Phase III Win in ALS The first study, called FUSION, evaluated ulefnersen for the treatment of pa... Full story

Yahoo Finance • last month

Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)

– Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential – – IgAN is a progressive kidney disease that is typically diagnosed in yo... Full story

Yahoo Finance • last month

Cathie Wood Makes a Big AI Bet and Cuts Bitcoin Exposure

This article first appeared on GuruFocus. Cathie Wood's Ark Invest made a notable shift inside its technology portfolio last week, adding heavily to CoreWeave while cutting several other AI and technology positions. Ark bought about 239,... Full story

Yahoo Finance • last month

NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication

Novartis NVS announced that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") has issued a positive opinion recommending marketing authorization for an additional indication of its arthrit... Full story

Yahoo Finance • 2 months ago

Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?

AstraZeneca's AZN stock has taken a beating recently, with the company facing several pipeline setbacks in the past few months. AZN's Recent Pipeline Setbacks In July, AstraZeneca announced the failure of a phase III study evaluating Wai... Full story

Yahoo Finance • 2 months ago

Novartis (NVS) and Ionis (IONS)’ Big Cholesterol Bet Comes Up Short in Late-Stage Trial

On September 5, 2026, Reuters reported that pelacarsen, an experimental drug from Novartis AG (NYSE:NVS) and partner Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) meant to lower a cholesterol-carrying particle called Lp(a), failed to reduce he... Full story

Yahoo Finance • 2 months ago

Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics

Company Logo Oligonucleotide Therapeutics Expand Beyond Rare Diseases as RNA Innovation, Targeted Delivery and Patient-Friendly Dosing Accelerate Adoption Dublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "Oligonucleotide Therapeutics Market Op... Full story

Yahoo Finance • 2 months ago

Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.

Novartis (NYSE: NVS) just reported its third clinical failure in only seven days. One of the company's pipeline setbacks triggered a ripple impact throughout one of the most hotly anticipated drug races in the biopharmaceutical industry.... Full story

Yahoo Finance • 2 months ago

Notable healthcare headlines for the week: UnitedHealth, Amgen, and CooperCompanies in focus

Wall Street rallied on Friday after the latest consumer inflation report came in broadly in line with expectations, helping ease concerns over price pressures and supporting a rebound across risk assets. On Friday, the Dow Jones Industria... Full story

Yahoo Finance • 2 months ago

BofA Sees Limited Damage from Novartis (NVS)’ Pelacarsen Miss While Citi Looks Towards Ionis (IONS)

Novartis AG's (NYSE:NVS) pelacarsen failed an important test. Although the experimental medicine lowered lipoprotein(a), or Lp(a), it did not produce a statistically significant reduction in cardiovascular events in the Phase 3 Lp(a)HORIZO... Full story

Yahoo Finance • 2 months ago

Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?

Royalty Pharma plc (NASDAQ:RPRX) disclosed that pelacarsen failed the Phase 3 Lp(a)HORIZON cardiovascular-outcomes trial conducted by Novartis AG (NYSE:NVS). The randomized, double-blind study enrolled 8,323 patients with elevated lipoprot... Full story

Yahoo Finance • 2 months ago

Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall

Novartis AG NVS announced that the late-stage HARBOR study evaluating del-desiran in people living with myotonic dystrophy type 1 (DM1) failed to meet the primary endpoint. Del-desiran is an investigational antibody oligonucleotide conjug... Full story

Yahoo Finance • 2 months ago

Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?

It has been about a month since the last earnings report for Theravance Biopharma (TBPH). Shares have added about 0.8% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend conti... Full story